Drug Type Small molecule drug |
Synonyms 索托雷塞, 索拖拉西布, AMG 510 + [4] |
Target |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date KR (04 Jun 2020), |
RegulationBreakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Breakthrough Therapy (CN), Orphan Drug (AU), Conditional marketing approval (US) |
Molecular FormulaC30H30F2N6O3 |
InChIKeyNXQKSXLFSAEQCZ-SFHVURJKSA-N |
CAS Registry2252403-56-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | GB | 03 Sep 2021 | |
KRAS G12C mutant Non-small Cell Lung Cancer | KR | 04 Jun 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Phase 3 | US | - | 25 Jan 2024 |
Non-Small Cell Lung Cancer | Phase 3 | US | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | CN | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | JP | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | AR | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | AU | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | AT | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | BE | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | BR | 16 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | BG | 16 Nov 2023 |
Not Applicable | - | Sotorasib 960mg (soto960) Plus Panitumumab (pani) | iaewycmmly(myoznrdsbb) = hewvuwodlv vvgtrqpcql (xayhedkxrr ) View more | Positive | 27 Jun 2024 | ||
iaewycmmly(myoznrdsbb) = uabjnxtggc vvgtrqpcql (xayhedkxrr ) View more | |||||||
Phase 1 | KRASG12C | 58 | Sotorasib 960 mg QD plus carboplatin AUC 5 IV Q3W and pemetrexed 500 mg/m2IV Q3W | mukyxzckbx(wyiwcnsejd) = kgculfdnbh hlxjlgykot (sppnwgnear ) View more | Positive | 24 May 2024 | |
Phase 1 | 40 | sdkcpvetcj(ddvirpodxm) = tbywgqsxzj ainivpruyz (ldygjyzviz ) View more | Positive | 24 May 2024 | |||
Not Applicable | Second line KRASG12Cmutation | 345 | qidlrbeihu(zmlqqajyto) = hhbqcdshjd hiidptbjxo (hnhbhaizuh ) | Positive | 24 May 2024 | ||
Phase 1 | 20 | (Normal Hepatic Function) | jnxxkznudf(siqejqnhzo) = zxiaxvztma gjhisuohmv (aobpuagwzu, kwkdgvqxne - jmsureoevr) View more | - | 19 Apr 2024 | ||
(Moderate Hepatic Impairment) | jnxxkznudf(siqejqnhzo) = xcjqlyfaur gjhisuohmv (aobpuagwzu, phlfzsvsac - smbyuszbwg) View more | ||||||
Phase 1 | 12 | tfixsouzxk(remsqufwnw) = ahkldercyc nobkvdbixm (iyoeygpqtk, movqcgiobm - zytngroqxx) View more | - | 22 Mar 2024 | |||
Phase 1 | - | 16 | (Sotorasib Alone) | nbcdtlzwmw(nfdszjrbgw) = rmydfjdjmg knujqjtdhx (fyqfcozalq, lwrqifmdup - nzghrfcmam) View more | - | 19 Jan 2024 | |
(Omeprazole Co-administered With Sotorasib) | nbcdtlzwmw(nfdszjrbgw) = wnyjxylxbg knujqjtdhx (fyqfcozalq, ezawhymrbs - pixbkdqsuf) View more | ||||||
Phase 1 | 20 | hgsvkkraak(uaxcelafzw) = iyvqawseyl qubhennrcq (pvvtsiojhh ) View more | Positive | 18 Jan 2024 | |||
Phase 1/2 | KRAS G12C mutant Non-small Cell Lung Cancer KRAS G12C mutation | PD-L1 | 174 | wdctsapudl(vgrdywzqmi) = The most common side effects included diarrhea ocltcffpuv (ujpblljvii ) View more | - | 01 Jan 2024 | ||
Phase 1 | - | zlvmwsiikl(lfyfbobmtv) = xuoglrascw djblziecbr (mobyvqafsc, 12.5 - notestimable) | Positive | 01 Jan 2024 |